Trials / Completed
CompletedNCT06444867
A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968
An Open-label, Phase 1b, Multi-site Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following a Single Dose of LEO 158968 in Subjects With Gout Flares
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the study is to evaluate the effect on pain of a single, subcutaneous (SC) dose of LEO 158968 in participants with gout flares.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 158968 | SC injection |
Timeline
- Start date
- 2024-12-06
- Primary completion
- 2025-09-18
- Completion
- 2025-09-18
- First posted
- 2024-06-06
- Last updated
- 2026-04-08
Locations
3 sites across 3 countries: France, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT06444867. Inclusion in this directory is not an endorsement.